Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Description

1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.

Conditions

Age-Related Macular Degeneration

Talk to us

Study Overview

On this page

Study Details

Study overview

1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

Condition
Age-Related Macular Degeneration
Intervention / Treatment

-

Contacts and Locations

Fargo

Bergstrom Eye Research LLC, Fargo, North Dakota, United States, 58103

Erie

Erie Retina Research, Erie, Pennsylvania, United States, 16507

Dallas

Retina Foundation of the Southwest, Dallas, Texas, United States, 75231

Madison

University Station Eye Care Clinic, Madison, Wisconsin, United States, 53705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants greater than or equal to 50 years of age at time of signing Informed Consent Form
  • * Willing to comply with all study procedures and sign the Informed Consent Form (ICF)
  • * Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.
  • * Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed.
  • * Unable to acquire adequate quality images, as evaluated by the Central Reading Center
  • * Severe vision loss requiring urgent surgery
  • * Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light
  • * A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study
  • * Unwilling to sign informed consent form
  • * Currently or previously enrolled in an interventional AMD clinical trial

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Wisconsin, Madison,

Amitha Domalpally, MD, PhD, PRINCIPAL_INVESTIGATOR, UW School of Medicine and Public Health

Study Record Dates

2026-11